Literature DB >> 8640333

Alterations of insulin response to different beta cell secretagogues and pancreatic vascular resistance induced by N omega-nitro-L-arginine methyl ester.

R Gross1, M Roye, M Manteghetti, D Hillaire-Buys, G Ribes.   

Abstract

1. We studied a possible interplay of pancreatic NO synthase activity on insulin secretion induced by different beta cell secretagogues and also on pancreatic vascular bed resistance. 2. This study was performed in the isolated perfused pancreas of the rat. Blockage of NO synthase was achieved with Nw-nitro-L-arginine methyl ester (L-NAME); The specificity of the antagonist was checked by using its D-enantiomer as well as by substitutive treatments with sodium nitroprusside (SNP) as a NO donor in studies of glucose-induced insulin secretion. 3. Arginine (5 mM) induced a monophasic response which was, in the presence of L-NAME at equimolar concentration, very strongly potentiated and converted into a 13 times higher biphasic one. D-NAME (5 mM) was only able to induce a 3 times higher response, but provoked a similar vasoconstrictor effect. 4. The small biphasic insulin secretion induced by L-leucine (5 mM) was also strongly enhanced, by 8 times, in the presence of L-NAME (5 mM) vs 2 times in the presence of D-NAME (5 mM). 5. beta cell responses to KCl (5 mM) and tolbutamide (0.185 mM) were only slight increased by L-NAME (5 mM) to values not far from the sum of the effects of L-NAME and of the two drugs alone. D-NAME (5 mM) was totally ineffective on the actions of both secretagogues. 6. L-NAME, infused 15 min before and during a rise in glucose concentration from 5 to 11 mM, was able in the low millimolar range (0.1-0.5 mM) to blunt the classical biphasic pattern of beta cell response to glucose and, at 5 mM, to convert it into a significantly greater monophasic one. In contrast, D-NAME (5 mM) was unable to induce similar effects. 7. SNP alone at 3 microM was ineffective but at 30 microM substantially reduced to second phase of insulin response to glucose; however, at both concentrations the NO donor partly reversed alterations in insulin secretion caused by L-NAME (5 mM) and restored a biphasic response.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8640333      PMCID: PMC1908956          DOI: 10.1111/j.1476-5381.1995.tb16399.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  30 in total

1.  Pathologic anatomy of the pancreas in juvenile diabetes mellitus.

Authors:  W Gepts
Journal:  Diabetes       Date:  1965-10       Impact factor: 9.461

2.  Nitric oxide: a cytotoxic activated macrophage effector molecule.

Authors:  J B Hibbs; R R Taintor; Z Vavrin; E M Rachlin
Journal:  Biochem Biophys Res Commun       Date:  1988-11-30       Impact factor: 3.575

3.  The nitric oxide synthase II inhibitor NG-nitro-L-arginine stimulates pancreatic islet insulin release in vitro, but not in the perfused pancreas.

Authors:  L Jansson; S Sandler
Journal:  Endocrinology       Date:  1991-06       Impact factor: 4.736

4.  Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo.

Authors:  D D Rees; R M Palmer; R Schulz; H F Hodson; S Moncada
Journal:  Br J Pharmacol       Date:  1990-11       Impact factor: 8.739

5.  Macrophage oxidation of L-arginine to nitrite and nitrate: nitric oxide is an intermediate.

Authors:  M A Marletta; P S Yoon; R Iyengar; C D Leaf; J S Wishnok
Journal:  Biochemistry       Date:  1988-11-29       Impact factor: 3.162

6.  Identification of inhibitors of nitric oxide synthase that do not interact with the endothelial cell L-arginine transporter.

Authors:  R G Bogle; S Moncada; J D Pearson; G E Mann
Journal:  Br J Pharmacol       Date:  1992-04       Impact factor: 8.739

7.  Insulin secretion from pancreatic B cells caused by L-arginine-derived nitrogen oxides.

Authors:  H H Schmidt; T D Warner; K Ishii; H Sheng; F Murad
Journal:  Science       Date:  1992-02-07       Impact factor: 47.728

8.  Nitric oxide as an inhibitory non-adrenergic non-cholinergic neurotransmitter.

Authors:  H Bult; G E Boeckxstaens; P A Pelckmans; F H Jordaens; Y M Van Maercke; A G Herman
Journal:  Nature       Date:  1990-05-24       Impact factor: 49.962

9.  L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation.

Authors:  R M Palmer; D D Rees; D S Ashton; S Moncada
Journal:  Biochem Biophys Res Commun       Date:  1988-06-30       Impact factor: 3.575

Review 10.  The inducible form of nitric oxide synthase (iNOS) in insulin-producing cells.

Authors:  D L Eizirik; F Leijerstam
Journal:  Diabete Metab       Date:  1994 Mar-Apr
View more
  8 in total

1.  Interaction of the islet nitric oxide system with L-arginine-induced secretion of insulin and glucagon in mice.

Authors:  B Akesson; H Mosén; G Panagiotidis; I Lundquist
Journal:  Br J Pharmacol       Date:  1996-10       Impact factor: 8.739

2.  Study of the mechanisms involved in adenosine-5'-O-(2-thiodiphosphate) induced relaxation of rat thoracic aorta and pancreatic vascular bed.

Authors:  B Saïag; D Hillaire-Buys; J Chapal; P Petit; D Pape; B Rault; H Allain; M M Loubatières-Mariani
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

3.  Total parenteral nutrition modulates hormone release by stimulating expression and activity of inducible nitric oxide synthase in rat pancreatic islets.

Authors:  A Salehi; M Ekelund; R Henningsson; I Lundquist
Journal:  Endocrine       Date:  2001-11       Impact factor: 3.633

4.  Influence of nitric oxide modulators on cholinergically stimulated hormone release from mouse islets.

Authors:  B Aring;kesson; I Lundquist
Journal:  J Physiol       Date:  1999-03-01       Impact factor: 5.182

5.  Increased neuronal nitric oxide synthase dimerisation is involved in rat and human pancreatic beta cell hyperactivity in obesity.

Authors:  K Mezghenna; P Pomiès; A Chalançon; F Castex; J Leroy; N Niclauss; B Nadal; L Cambier; C Cazevieille; P Petit; R Gomis; T Berney; R Gross; A D Lajoix
Journal:  Diabetologia       Date:  2011-08-18       Impact factor: 10.122

6.  The ellagitannin metabolite urolithin C is a glucose-dependent regulator of insulin secretion through activation of L-type calcium channels.

Authors:  Morgane Bayle; Jérémie Neasta; Margherita Dall'Asta; Guillaume Gautheron; Anne Virsolvy; Jean-François Quignard; Estelle Youl; Richard Magous; Jean-François Guichou; Alan Crozier; Daniele Del Rio; Gérard Cros; Catherine Oiry
Journal:  Br J Pharmacol       Date:  2019-10-10       Impact factor: 8.739

7.  Excessive islet NO generation in type 2 diabetic GK rats coincides with abnormal hormone secretion and is counteracted by GLP-1.

Authors:  Albert Salehi; Sandra Meidute Abaraviciene; Javier Jimenez-Feltstrom; Claes-Göran Ostenson; Suad Efendic; Ingmar Lundquist
Journal:  PLoS One       Date:  2008-05-14       Impact factor: 3.240

8.  The Effect of Cinnamaldehyde on iNOS Activity and NO-Induced Islet Insulin Secretion in High-Fat-Diet Rats.

Authors:  Zomorrod Ataie; Mohammad Dastjerdi; Khadijeh Farrokhfall; Zahra Ghiravani
Journal:  Evid Based Complement Alternat Med       Date:  2021-07-13       Impact factor: 2.629

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.